Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Calabresi F, Paridaens R, Monfardini S, Wolff J, Loos WJ, Verweij J, Pavlidis N, Hanauske AR; EORTC Early Clinical Studies Group.
Schellens JH, et al. Among authors: monfardini s.
Anticancer Drugs. 2001 Aug;12(7):583-90. doi: 10.1097/00001813-200108000-00004.
Anticancer Drugs. 2001.
PMID: 11487714
Clinical Trial.